⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28716424 | 0.96 | — | — | |
| SCHEMBL14576195 | 0.77 | — | — | |
| SCHEMBL28526434 | 0.77 | HIF1A (0.67) | — | |
| SCHEMBL26077562 | 0.77 | — | — | |
| SCHEMBL797544 | 0.77 | — | — | |
| SCHEMBL6100699 | 0.77 | HIF1A (0.67) | — | |
| SCHEMBL2670598 | 0.77 | HIF1A (0.67) | — | |
| SCHEMBL7565118 | 0.74 | CXCR4 (0.50) | — | |
| Hydrochloric Acid SCHEMBL5564783 | 0.73 | HIF1A (0.60) | — | |
| SCHEMBL9534762 | 0.72 | CXCR4 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622984-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2026-05-12 | — | — | US | claimed |
| US-20260061084-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2026-03-05 | — | — | US | claimed |
| US-12447217-B2 | Fibroblast activation protein (FAP) inhibitors, FAP conjugates, and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2025-10-21 | — | — | US | claimed |
| EP-4590346-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| CN-119069790-A | Application of poly-oxazine compound in electrolyte, preparation method and application of electrolyte, lithium ion battery and electric equipment | 比亚迪股份有限公司 | 2024-12-03 | — | — | CN | claimed |
| US-20240172953-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-05-30 | — | — | US | claimed |
| US-20240131203-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-04-25 | — | — | US | claimed |
| WO-2024064968-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-03-28 | — | — | WO | claimed |
| EP-2520568-B1 | Spirocyclic nitriles as inhibitors of protease | SANOFI SA (FR) | 2015-09-09 | — | — | EP | claimed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | claimed |
| EP-2238127-B1 | PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-15 | — | — | EP | claimed |
| EP-2032535-B1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | claimed |
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | claimed |
| US-20110039829-A1 | PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | claimed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | claimed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | claimed |
| CN-101663293-A | Quinoline-carboxamide derivatives as p2y12 antagonists | SANOFI AVENTIS | 2010-03-03 | — | — | CN | claimed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | claimed |
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2009-11-05 | — | — | US | claimed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | claimed |